drugset / Trial / NCT07013643

A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity

NCT07013643

Phase 1 Recruiting 50 enrolled AstraZeneca
Non-randomizedSequentialOpen-labelTreatment

Summary

This study will measure the effects of multiple doses of AZD6234, AZD9550 and a combination of AZD9550 and AZD6234 given as injection(s) on pharmacokinetics (PK) of combined oral contraceptive (CoC) ethinyl estradiol (EE)/levonorgestrel (LEVO) in healthy female participants with obesity.

Timeline

Start
2025-06-04
Primary completion
2027-07-09
Completion
2027-07-09

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD6234 Small activating RNA (saRNA) Subcutaneous
Subject AZD9550 Other / unclassified Subcutaneous
Subject Levonorgestrel Small molecule Oral
Subject ethinyl estradiol Small molecule Oral
Background Acetaminophen Small molecule Oral

Indications

No indication recorded.